BioRay Pharmaceutical Co., Ltd. ("BioRay") announced that the National Medical Products Administration (NMPA) has accepted the clinical trial application for its self-developed Class 1 innovative ...

Tubulis announced today that its second drug candidate, TUB-030, has entered clinical evaluation with successful dosing of ...

Enhertu is a HER2-directed antibody and topoisomerase inhibitor conjugate. Approval of the new indication was based on data from the phase 3 DESTINY-Breast06 trial (ClinicalTrials.gov Identifier ...

StockNews.com began coverage on shares of Sorrento Therapeutics (NASDAQ:SRNE – Free Report) in a research note released on Sunday morning. The firm issued a hold rating on the biopharmaceutical ...

The authors note that vaccine-specific changes to the 2025 schedule compared with the 2024 schedule include new and updated recommendations for the COVID-19 vaccine, influenza vaccines, meningococcal ...